Loading
A phase 3 trial in lung cancer, run by Fudan University, not yet recruiting.
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020) is a phase 3, interventional study registered as NCT06102161 by Fudan University, with a registry enrolment figure of 286 participants, started 2023-11 and due to reach its primary completion in 2025-11. Interventions recorded: Wedge resection. Conditions listed: Lung Cancer; Wedge Resection; Ground-glass Opacity. Primary outcome: 5-year overall survival. Lung eligibility wording from the registry: "Not receiving lung cancer surgery before;". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/